Please assess the completion status of the following clinical trial:

Trial Title: MemoryXL Effects on Mild Cognitive Impairment Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* MCI patients diagnosed at the VAMC Center for Alzheimers and Neurodegenerative Disorder (CANDO).~* Clinical Dementia Rating (CDR) score of 0.5.~* fluent in English.~* able to ambulate to the outpatient clinic and research laboratory~* have sight and hearing levels sufficient to complete neuropsychological testing.~* free from bipolar disorder and terminal illnesses such as cancer.~* must live with a spouse or adult relative who will record nutriceutical ingestion daily.~* subjects will be consecutively diagnosed patients from all ethnic groups.~Exclusion Criteria:~* patients from protected categories such as prisoners and pregnant women.~* any MCI subject who develops a life-threatening disease such as terminal cancer, stroke, brain trauma, debilitating heart attack, etc.~* indication of inability to make decisions regarding study participation.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Memory XL (Type: EXPERIMENTAL): Subjects will take 2 Memory XL pills daily for 12 months (a vitamin nutriceutical developed by Thomas Shea, Ph.D.).~Mild Cognitive Impairment (MCI) patients, who met inclusion/exclusion criteria, were assessed initially using 3 cognitive tests and 4 behavioral questionnaires, before they began ingesting pills assigned to them by VAMC Research Pharmacist. Each 3 months thereafter, they returned to lab to be reassessed using same instruments, and to receive the next batch of study pills from the Pharmacist. The last assessment was when the patient had just finished 12 months of pill ingestion.
- placebo (Type: PLACEBO_COMPARATOR): Subjects diagnosed with MCI took two placebo pills daily for 12 months; these pills are formulated to look and taste the same as the nutriceutical being studied, Memory XL, so study was double-blind. Procedures for this arm are exactly the same as the MEMORY XL arm.~MCI subjects were assessed using 3 cognitive tests and 4 behavioral questionnaires, before they began ingesting the pills assigned to them by the Research Pharmacist at VAMC. Each 3 months thereafter, they returned to lab to be reassessed using the same instruments, and to receive next batch of study pills. Last assessment was when patient had completed 12 months of pill ingestion.

Based on this trial design, predict the completion outcome and termination type (if applicable).